OSAKA -- As nations scramble to develop vaccines for the coronavirus, Takara Bio is at the forefront of Japan's efforts, tapping its four decades of gene-editing experience to help develop a DNA-based approach that has never been used in humans before.
Coronavirus
Takara Bio drives Japan's quest for a coronavirus vaccine
Pharmaceutical maker boasts twin strengths in testing and DNA technology
Takara Bio will produce a vaccine form the DNA of the coronavirus, an approach never used in humans before. © Reuters
Read Next
Latest on Coronavirus
